How Can a Drug that CAUSES Leukemia, TB, and Listeria Remain on the Market?

FDA’s own employees are starting to question the agency’s reckless drug approval process.

In 1998, the FDA approved a new class of anti-inflammatory drugs called TNF-alpha blockers. The best-known drugs in this class are Enbrel and Humira, which are used to treat juvenile rheumatoid arthritis, Crohn’s disease, and other inflammatory diseases.

Because TNF-alpha blockers SUPPRESS the IMMUNE SYSTEM, patients are at increased risk of developing serious infections that may lead to hospitalization or death due to bacterial, mycobacterial, fungal, viral, parasitic, and other opportunistic pathogens.